GGPeps declines, for the 15th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Archive — June 2025
Page 5 of 5 of this archive, newest first.
A shortage listing ends. 13 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The quiet end of Calder Vale Peptides of Skipton
A proper account of an operation that existed, and of what closing it cost.
What we asked twenty suppliers about stability data
A retest date says that material should be re-examined before use. An expiry date says it should not be used. The trade uses the second word for the first concept.
Deamidation, oxidation, and the two shifts worth memorising
What would be needed to catch each of these, and what it would cost.
Escalating onto a rising curve
The four-week step exists because four to five weeks is approximately how long a once-weekly drug takes to stop rising at a fixed dose. That is a good reason, and it is not…
VendorInvestigate result on a Shanghai mazdutide lot lands 2.8 points below the supplier’s figure
The supplier has not disputed the finding. It has not explained the gap either.
What changed at FGP in June, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
Inspectors cite the consolidator trading as Meridian Freight Partners over sterility assurance
The observation that closes a facility is rarely the dramatic one.